Nemani, 1,958 patient fluvoxamine prophylaxis study: 30% more cases [p=0.16] https://c19p.org/nemani
copied to clipboard
Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State–wide Psychiatric Hospital System
et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.10743
Retrospective 1,958 consecutive psychiatric patients in the USA, showing higher cases and lower mortality with fluvoxamine, without statistical significance, and there was only 25 fluvoxamine patients.
|
risk of death, 97.5% lower, RR 0.03, p = 1.00, treatment 0 of 16 (0.0%), control 38 of 953 (4.0%), NNT 25, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of case, 29.8% higher, RR 1.30, p = 0.16, treatment 16 of 25 (64.0%), control 953 of 1,933 (49.3%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Nemani et al., 5/6/2022, retrospective, USA, North America, peer-reviewed, 12 authors, study period 8 March, 2020 - 1 July, 2020.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.